公开(公告)号：US20180346452A1

公开(公告)日：2018-12-06

申请号：US15830634

申请日：2017-12-04

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masami YAMADA ,  Shinkichi Suzuki ,  Takahiro Sugimoto ,  Minoru Nakamura ,  Hiroki Sakamoto ,  Makoto Kamata

IPC: C07D405/14 ,  C07D405/04 ,  A61K31/045 ,  C07D403/10 ,  C07D403/04 ,  C07D401/14 ,  C07D401/10 ,  C07D401/06 ,  C07D209/46 ,  A61K31/55 ,  A61K31/445 ,  A61K31/4439 ,  A61K31/4406 ,  A61K31/4155 ,  A61K31/4035 ,  A61K31/325 ,  A61K31/13 ,  C07D471/04

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US09775827B2

公开(公告)日：2017-10-03

申请号：US15488002

申请日：2017-04-14

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masami Yamada ,  Shinkichi Suzuki ,  Takahiro Sugimoto ,  Minoru Nakamura ,  Hiroki Sakamoto ,  Makoto Kamata

IPC: C07D209/46 ,  C07D403/10 ,  C07D405/14 ,  C07D403/04 ,  C07D401/10 ,  C07D401/14 ,  A61K31/4035 ,  A61K31/445 ,  A61K31/55 ,  A61K31/325 ,  A61K31/4155 ,  A61K31/4439

CPC classification number: C07D405/14 ,  A61K31/045 ,  A61K31/13 ,  A61K31/325 ,  A61K31/4035 ,  A61K31/4155 ,  A61K31/4406 ,  A61K31/4439 ,  A61K31/445 ,  A61K31/55 ,  C07D209/46 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D471/04

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US08940758B2

公开(公告)日：2015-01-27

申请号：US13944370

申请日：2013-07-17

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takahiko Taniguchi ,  Masato Yoshikawa ,  Kasei Miura ,  Tomoaki Hasui ,  Eiji Honda ,  Keisuke Imamura ,  Makoto Kamata ,  Haruhi Ando

IPC: A61K31/4353 ,  A61K31/437 ,  A61K31/4355

CPC classification number: A61K31/4353 ,  A61K31/4355 ,  A61K31/437 ,  A61K31/4427 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4985 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/52 ,  A61K31/522 ,  A61K31/551 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D413/14 ,  C07D471/04 ,  C07D471/14 ,  C07D473/00 ,  C07D473/28 ,  C07D487/04 ,  C07D495/04 ,  C07D498/04 ,  C07D498/08 ,  C07D519/00 ,  C07F7/10

Abstract: The present invention provides a compound which has the effect of PDE inhibition, and which is useful as an agent for preventing or treating schizophrenia. The compound is represented by the formula (I): wherein the symbols are defined in the specification.

Abstract translation: 本发明提供具有PDE抑制作用的化合物，其可用作预防或治疗精神分裂症的药剂。 化合物由式（I）表示：其中符号在说明书中定义。